B of A Securities Reiterates Rating on TYRA $TYRA
Key Points
- B of A Securities now rates Tyra Biosciences, Inc. ($TYRA) "buy" with a $42 target.
- B of A Securities's $42 price target implies 55.61% upside from Tyra Biosciences, Inc.'s ($TYRA) current $26.99 share price.
- The Street's average $TYRA price target is $50.82 (Strong Buy).
- $TYRA last traded around $26.99.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B of A Securities reiterated its rating on Tyra Biosciences, Inc. ($TYRA) to a "buy" rating in a recent research note and set a price target of $42, a 55.61% upside from the current price.
Tyra Biosciences, Inc. Stock Up 8.2%
Shares of Tyra Biosciences, Inc. ($TYRA) traded around $26.99 on Saturday, up 8.2% for the day.
Tyra Biosciences, Inc. Earnings
Analysts Set New Price Targets
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Get Tyra Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TYRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.